Zymeworks
ZYME· Manufacturing· Fiscal year ends in December
Kenneth Galbraith is the CEO of Zymeworks and was paid $6.6M in FY2025 (Dec), up 26%.
Executives3
See all- 1Kenneth GalbraithCEO, President & ChairFY2025
- 2Paul A. Moore, CSOFY2025
- 3Jeffrey SmithFormer Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allZymeworks paid its 3 named executives $11.0M in total in FY2025 (Dec). CEO Kenneth Galbraith was paid $6.6M of that.
| Name | |||
|---|---|---|---|
| Kenneth GalbraithCEO, President & Chair | Not disclosed | ||
| Paul A. Moore, CSO | Not disclosed | ||
| Jeffrey SmithFormer Chief Medical Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers19
See allThe FY2025 (Dec) proxy of Zymeworks names 19 peer companies for pay. Among Zymeworks and these peers, CEO pay was 4th highest of 9 and total shareholder return was 2nd highest of 9.
4th highest of 9in Zymeworks and its pay peers, FY2025 (Dec) by CEO pay:
2nd highest of 9in Zymeworks and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Susan MahonyLead independent director · 6 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Carlos CampoyDirector · 2 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Alessandra CesanoDirector · 1 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
- Robert E. LandryDirector · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Oct 26, 2026 | FY2025 |
| Annual report | 10-K | Mar 2, 2026 | FY2025 |
| Proxy statement | DEF 14A | Nov 10, 2025 | FY2024 |
| Annual report | 10-K | Mar 5, 2025 | FY2024 |
| Proxy statement | DEF 14A | Oct 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 6, 2024 | FY2023 |